You are here

Primary Endpoint Met in Phase IV Study of Toviaz (Fesoterodine Fumarate) for Overactive Bladder

The 14-week randomized, parallel group, placebo-controlled, double-blind multicentre study assessed Toviaz 8 mg in 642 patients with OAB who had been taking Detrol LA 4 mg for 2 weeks and had less than a 50% reduction in UUI episodes. After open-label treatment with Detrol LA 4 mg, treatment with Toviaz 4 mg was started for 1 week, followed by treatment with Toviaz 8 mg.

The study demonstrated that Toviaz 4 mg for 1 week followed by Toviaz 8 mg significantly reduced the average number of UUI episodes (–2.37 episodes from baseline) per 24 hours (P

The safety and tolerability profiles of fesoterodine and tolterodine were consistent with previous studies. The most common treatment-emergent adverse events for both drugs were dry mouth and constipation.

Further analyses will be conducted, and a publication of the comprehensive results is planned for a later date.

Approximately 33 million American adults are estimated to have OAB symptoms.

Source: Pfizer

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs